Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults (18-65 years)~* Infected with S. stercoralis (positive)~* Absence of major systemic illnesses~* Written informed consent~Exclusion Criteria:~* Any abnormal medical conditions or chronic disease~* Negative diagnostic result for S. stercoralis~* No written informed consent by the individual.~* Pregnant and lactating women.~* Recent use of an anthelmintic drug (within past 4 weeks)~* Attending other clinical trials during the study~* Known allergy to study medications (i.e. moxidectin, ivermectin)~* Currently taking medications with known interaction (i.e. for warfarin)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Moxidectin (Type: EXPERIMENTAL): 8 mg Moxidectin at day 0 administered orally
- Ivermectin (Type: EXPERIMENTAL): 200 ug/kg Ivermectin at day 0 administered orally

Based on this trial design, predict the completion outcome and termination type (if applicable).